Opioid Withdrawal Symptom Mitigation Data Can Support A Labeling Claim
Executive Summary
While symptom reduction is a clinically meaningful benefit that can support an indication, data on withdrawal treatment completion can provide confirmatory evidence of a drug's effect, US FDA advisory committee members say in their review of US WorldMeds' lofexidine.
You may also be interested in...
Keeping Track: A Diverse Array Of Approvals, A CRL For Evolus' Botox Competitor, And Coherus Refiles Neulasta Biosimilar
The latest drug development news and highlights from our US FDA Performance Tracker.
Opioid Use Disorder: Is Reduced Usage A Better Endpoint Than Abstinence?
Some at patient-focused drug development meeting argue that cutting opioid use should not be considered treatment failure and that medications allowing controlled opioid use may be beneficial.
Lofexidine Gets US FDA Panel Nod For Mitigating Opioid Withdrawal Symptoms
But Psychopharmacologic Drugs Advisory Committee says US WorldMeds' second proposed indication for facilitating completion of opioid discontinuation treatment is not supported by data from two short-term studies in an 'idealized' population.